{
    "relation": [
        [
            "",
            "Peginterferon Alfa-2a 90 Mcg/Week",
            "Standard of Care Followup"
        ],
        [
            "Description",
            "Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months",
            "Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment"
        ]
    ],
    "pageTitle": "Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00006164?sect=X4015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988650.6/warc/CC-MAIN-20150728002308-00159-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 853356143,
    "recordOffset": 853342171,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Peginterferon alfa-2a + Ribavirin Drug: Peginterferon alfa-2a Interventions: Chronic Hepatitis C Cirrhosis, Liver Fibrosis, Liver Hepatic Cirrhosis Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional Study Type: Results First Received: June 9, 2009 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Peginterferon Alfa-2a 90 Mcg/Week \u00a0 \u00a0 Standard of Care Followup \u00a0 STARTED \u00a0 \u00a0 517 \u00a0 \u00a0 533 \u00a0 COMPLETED \u00a0 \u00a0 447 [1] \u00a0 452 [2] NOT COMPLETED \u00a0 \u00a0 70 \u00a0 \u00a0 81 \u00a0 Withdrew or lost to follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 70 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 81 \u00a0 [1] 70 Withdrew or were lost to followup; 158 Discontinued peginterferon but were followed [2] 81 Withdrew or were lost to followup; 9 took peginterferon outside of protocol",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}